---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-382838"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2026-09-04T12:30:05+00:00"
generated_at: "2026-09-04T12:30:36.531406+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Quince Therapeutics receives Nasdaq delisting notice after negative stockholders' equity

## Summary
- On Aug 31, 2026, Nasdaq notified QNCX that stockholders' equity was ($35.3M) as of June 30, 2026, below $10M minimum.
- Company has until Oct 15, 2026 to submit compliance plan; Nasdaq may grant extension to Feb 27, 2027.
- Shares continue trading on Nasdaq Global Select under QNCX; no immediate delisting effect.
- Filed initial listing application to move to Nasdaq Capital Market; may rename to IRulya Therapeutics Inc. under IRLA.
- Management evaluating alternatives; no assurance of regaining compliance or listing approval.

## SEC filing metadata
- accession: 0001193125-26-382838
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2026-09-04T12:30:05+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312526382838/0001193125-26-382838-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312526382838/d105528d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-382838
- JSON: https://secwatch.observer/filing/0001193125-26-382838.json
- Plain text: https://secwatch.observer/filing/0001193125-26-382838.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.